Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 8/20 | 0.57 |
| ▸ | MEN1 | O00255 | 4/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | HPGD | P15428 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.44 |
| ▸ | THPO | P40225 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13143432 | 1.00 | KMT2A (0.57) | KMT2AMEN1SMN1; SMN2HSD17B10NPSR1 | |
| SCHEMBL1133971 | 1.00 | KMT2A (0.57) | KMT2AMEN1SMN1; SMN2HSD17B10NPSR1 | |
| SCHEMBL11080172 | 0.89 | KMT2A (0.54) | KMT2AMEN1SMN1; SMN2HSD17B10NPSR1 | |
| SCHEMBL12229256 | 0.85 | LMNA (0.47) | KMT2AMEN1SMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL1133950 | 0.84 | KMT2A (0.55) | KMT2AMEN1SMN1; SMN2HSD17B10NPSR1 | |
| SCHEMBL1133962 | 0.84 | KMT2A (0.55) | KMT2AMEN1SMN1; SMN2HSD17B10NPSR1 | |
| SCHEMBL13143428 | 0.82 | KMT2A (0.53) | KMT2AMEN1SMN1; SMN2HSD17B10NPSR1 | |
| SCHEMBL13143430 | 0.82 | KMT2A (0.53) | KMT2AMEN1SMN1; SMN2HSD17B10NPSR1 | |
| SCHEMBL13143429 | 0.82 | KMT2A (0.53) | KMT2AMEN1SMN1; SMN2HSD17B10NPSR1 | |
| Sumacetamol SCHEMBL5185790 | 0.81 | GAA (0.55) | KMT2AMEN1SMN1; SMN2HSD17B10NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4181719-A | Analgesic N-acetyl-para-aminophenyl N'-acetylaminothioalkanoates | STERLING DRUG INC. (US) | 1980-01-01 | — | — | US | claimed |
| US-11566081-B2 | Anti-acetaminophen antibodies and acetaminophen protein adducts | BIOVENTURES, LLC (US) | 2023-01-31 | — | — | US | disclosed |
| EP-3227681-B1 | ANTI-ACETAMINOPHEN ANTIBODIES AND ACETAMINOPHEN PROTEIN ADDUCTS | BIOVENTURES LLC (US) | 2020-10-21 | — | — | EP | disclosed |
| US-20200131278-A1 | ANTI-ACETAMINOPHEN ANTIBODIES AND ACETAMINOPHEN PROTEIN ADDUCTS | BIOVENTURES LLC (US) | 2020-04-30 | — | — | US | disclosed |
| US-10570216-B2 | Anti-acetaminophen antibodies and acetaminophen protein adducts | BIOVENTURES, LLC (US) | 2020-02-25 | — | — | US | disclosed |
| US-20170362340-A1 | ANTI-ACETAMINOPHEN ANTIBODIES AND ACETAMINOPHEN PROTEIN ADDUCTS | BIOVENTURES, LLC | 2017-12-21 | — | — | US | disclosed |
| EP-3227681-A2 | ANTI-ACETAMINOPHEN ANTIBODIES AND ACETAMINOPHEN PROTEIN ADDUCTS | Bioventures, LLC (US) | 2017-10-11 | — | — | EP | disclosed |
| EP-2453743-B1 | N-ACETYL CYSTEINE COMPOSITIONS AND THEIR USE IN IMPROVING THE THERAPEUTIC EFFICACY OF ACETAMINOPHEN | UNIV LELAND STANFORD JUNIOR (US) | 2017-04-12 | — | — | EP | disclosed |
| WO-2016090163-A2 | ANTI-ACETAMINOPHEN ANTIBODIES AND ACETAMINOPHEN PROTEIN ADDUCTS | BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS (US) | 2016-06-09 | — | — | WO | disclosed |
| US-8575217-B2 | Anti-inflammatory and antioxidant conjugates useful for treating metabolic disorders | GENMEDICA THERAPEUTICS SL (ES) | 2013-11-05 | — | — | US | disclosed |
| US-20110014285-A1 | N-ACETYL CYSTEINE COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC EFFICACY OF ACETAMINOPHEN | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2011-01-20 | — | — | US | disclosed |
| US-20100234452-A1 | Anti-Inflammatory and Antioxidant Conjugates Useful for Treating Metabolic Disorders | GENMEDICA THERAPEUTICS SL (ES) | 2010-09-16 | — | — | US | disclosed |
| US-20100234452-A1 | Anti-Inflammatory and Antioxidant Conjugates Useful for Treating Metabolic Disorders | GENMEDICA THERAPEUTICS SL (ES) | 2010-09-16 | — | — | US | disclosed |
| EP-0538268-A4 | TARGETED PROTECTION FROM CYTOTOXINS | — | 1993-05-12 | — | — | EP | disclosed |
| EP-0538268-A1 | TARGETED PROTECTION FROM CYTOTOXINS | THE UNIVERSITY OF CONNECTICUT (US) | 1993-04-28 | — | — | EP | disclosed |
| WO-1991017761-A1 | TARGETED PROTECTION FROM CYTOTOXINS | THE UNIVERSITY OF CONNECTICUT (US) | 1991-11-28 | — | — | WO | disclosed |
| US-4482495-A | CHEMICAL INTERMEDIATES FOR ANALGESICS | STERLING DRUG INC. (US) | 1984-11-13 | — | — | US | disclosed |
| US-4405800-A | ANALGESICS | STERLING DRUG INC. (US) | 1983-09-20 | — | — | US | disclosed |
| US-4361703-A | ANALGESICS | STERLING DRUG INC. (US) | 1982-11-30 | — | — | US | disclosed |
| US-4181719-A | Analgesic N-acetyl-para-aminophenyl N'-acetylaminothioalkanoates | STERLING DRUG INC. (US) | 1980-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234452-A1 | Anti-Inflammatory and Antioxidant Conjugates Useful for Treating Metabolic Disorders | HSD17B14, SORD, GPX4 | KMT2A 3962/4885MEN1 2842/4885SMN1; SMN2 2940/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.